159 related articles for article (PubMed ID: 20233612)
1. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.
Reinholz MM; Zinnen SP; Dueck AC; Dingli D; Reinholz GG; Jonart LA; Kitzmann KA; Bruzek AK; Negron V; Abdalla AK; Arendt BK; Croatt AJ; Sanchez-Perez L; Sebesta DP; Lönnberg H; Yoneda T; Nath KA; Jelinek DF; Russell SJ; Ingle JN; Spelsberg TC; Dixon HB; Karpeisky A; Lingle WL
Bone; 2010 Jul; 47(1):12-22. PubMed ID: 20233612
[TBL] [Abstract][Full Text] [Related]
2. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD
PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K
J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease.
Nyman JS; Merkel AR; Uppuganti S; Nayak B; Rowland B; Makowski AJ; Oyajobi BO; Sterling JA
Bone; 2016 Oct; 91():81-91. PubMed ID: 27423464
[TBL] [Abstract][Full Text] [Related]
5. Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.
Cruz JC; Alsina M; Craig F; Yoneda T; Anderson JL; Dallas M; Roodman GD
Exp Hematol; 2001 Apr; 29(4):441-7. PubMed ID: 11301184
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Zheng Y; Zhou H; Brennan K; Blair JM; Modzelewski JR; Seibel MJ; Dunstan CR
Bone; 2007 Feb; 40(2):471-8. PubMed ID: 17092788
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
[TBL] [Abstract][Full Text] [Related]
9. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
10. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Edwards CM; Mueller G; Roelofs AJ; Chantry A; Perry M; Russell RG; Van Camp B; Guyon-Gellin Y; Niesor EJ; Bentzen CL; Vanderkerken K; Croucher PI
Int J Cancer; 2007 Apr; 120(8):1657-63. PubMed ID: 17230522
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
12. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
14. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis.
Ooi LL; Zheng Y; Zhou H; Trivedi T; Conigrave AD; Seibel MJ; Dunstan CR
Bone; 2010 Oct; 47(4):795-803. PubMed ID: 20638491
[TBL] [Abstract][Full Text] [Related]
16. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Duivenvoorden WC; Vukmirović-Popović S; Kalina M; Seidlitz E; Singh G
Br J Cancer; 2007 May; 96(10):1526-31. PubMed ID: 17437017
[TBL] [Abstract][Full Text] [Related]
17. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
18. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
[TBL] [Abstract][Full Text] [Related]
19. [Effect of bisphosphonate on myeloma bone disease].
Abe M; Matsumoto T; Kosaka M
Rinsho Ketsueki; 2002 May; 43(5):349-52. PubMed ID: 12096484
[No Abstract] [Full Text] [Related]
20. Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway.
Ishikawa C; Matsuda T; Okudaira T; Tomita M; Kawakami H; Tanaka Y; Masuda M; Ohshiro K; Ohta T; Mori N
Br J Haematol; 2007 Feb; 136(3):424-32. PubMed ID: 17233845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]